Insuman Implantable

Insulin Human, the active ingredient in Insuman Implantable, is an insulin presented as an implantable formulation for intraperitoneal use. It is employed to regulate blood glucose levels in patients with diabetes mellitus, including type 1, type 2, and gestational diabetes, by providing continuous basal insulin delivery.

GNH USA supplies Insuman Implantable as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Insulin Human is used to manage blood glucose within the diabetes mellitus therapeutic pathway.

Type 1 Diabetes: provides continuous basal insulin to maintain fasting glucose levels. Type 2 Diabetes: added when oral antidiabetic agents fail to achieve target glycemic control. Gestational Diabetes: used when diet and oral medications are insufficient to control maternal glucose.

Insulin Human may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose symptoms such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or pain at the implant site. - Lipodystrophy: localized fat accumulation or loss. - Weight gain: increase in body weight due to improved glucose utilization. - Edema: mild fluid retention, especially in lower extremities.

Serious or Rare Side Effects: - Severe hypoglycemia: loss of consciousness or seizures. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin antibody formation: may alter insulin efficacy. - Lipohypertrophy with necrosis: severe tissue damage at implant site.

When using Insulin Human, several precautions should be observed to ensure safe and effective therapy.

Dose adjustment: individualize based on blood glucose monitoring and clinical response. Hypoglycemia monitoring: educate patients to recognize and treat low glucose promptly. Renal impairment: consider reduced clearance and adjust dosing as needed. Concomitant medications: review for agents that may potentiate or diminish insulin effect. Pregnancy and lactation: evaluate risk‑benefit; insulin is generally preferred when glycemic control is required. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Human can interact with other medicines, influencing its glucose‑lowering action or increasing adverse event risk.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms and prolong insulin effect. - MAO‑inhibitors: can potentiate insulin‑induced hypoglycemia. - Corticosteroids: may cause significant hyperglycemia, requiring insulin dose increase.

Moderate Interactions (Monitor Closely): - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides): additive hypoglycemia risk. - Diuretics (thiazides): may raise blood glucose, necessitating dose adjustment. - ACE inhibitors: can enhance insulin sensitivity, possibly requiring dose reduction.